Challenges and limitations of mesenchymal stem cell therapy for lung diseases in clinical trials DOI

Milena Barbosa Da Silva,

Patrícia R. M. Rocco, Fernanda F. Cruz

et al.

Expert Opinion on Emerging Drugs, Journal Year: 2025, Volume and Issue: unknown

Published: April 5, 2025

Language: Английский

Development and Optimization of an Ex Vivo Model of Corneal Epithelium Damage with 1-Heptanol: Investigating the Influence of Donor Clinical Parameters and MSC-sEV Treatment on Healing Capacity DOI Creative Commons
Filippo Bonelli, Seyedmohammad Moosavizadeh, E. Fasolo

et al.

The Ocular Surface, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

Citations

0
Extracellular vesicles derived from mesenchymal stem cells alleviate depressive-like behavior in a rat model of chronic stress DOI

Zaquer Suzana Munhoz Costa-Ferro,

Rita Cunha, Erik Aranha Rossi

et al.

Life Sciences, Journal Year: 2025, Volume and Issue: 366-367, P. 123479 - 123479

Published: Feb. 20, 2025

Language: Английский

Citations

0
Safety, Efficacy and Bio-Distribution Analysis of Exosomes Derived From Human Umbilical Cord Mesenchymal Stem Cells for Effective Treatment of Bronchopulmonary Dysplasia by Intranasal Administration in Mice Model DOI Creative Commons
Wanting Xu,

Xiaolin Jieda,

Yue Wu

et al.

International Journal of Nanomedicine, Journal Year: 2025, Volume and Issue: Volume 20, P. 2521 - 2553

Published: Feb. 1, 2025

Exosomes (Exos) derived from human umbilical cord mesenchymal stem cells (hUC-MSCs) hold great potential for treating bronchopulmonary dysplasia (BPD); however, safety concerns and effects of intranasal administration remain unexplored. This study aimed to explore the hUC-MSCs Exos investigate efficacy bio-distribution repeated in neonatal BPD models. Characteristics were analyzed. A subcutaneous tumor formation assay using a single dose or was conducted Crl:NU-Foxn1nu mice. Vital signs, biochemical indices, pathological alterations, 18F-FDG microPET/CT analysis examined. Pulmonary pathology, three-dimensional reconstructions, ultrastructural structures, vivo ex imaging analyses, enzyme-linked immunoassay assays, reverse transcription-quantitative polymerase chain reaction analyses lung tissues all documented following administration. satisfied specifications. mice did not exhibit overt toxicity carcinogenicity after 60 days observation. Repeated effectively alleviated injuries, restored pulmonary ventilation reconstruction, recovered endothelial cell layer integrity analysis. steadily accumulated postnatal day 1 14. also interrupted epithelial-mesenchymal transition inflammation reactions As nanoscale, non-cellular therapy, an effective, noninvasive treatment BPD. approach free toxic, tumorigenic risks repaired alveolar damage while interrupting with

Language: Английский

Citations

0
Challenges and limitations of mesenchymal stem cell therapy for lung diseases in clinical trials DOI

Milena Barbosa Da Silva,

Patrícia R. M. Rocco, Fernanda F. Cruz

et al.

Expert Opinion on Emerging Drugs, Journal Year: 2025, Volume and Issue: unknown

Published: April 5, 2025

Language: Английский

Citations

0